FiercePharmaOriginal article
{"a":[{"_":"FDA dings Alar over ‘extremely concerning’ ketamine claims","$":{"href":"/marketing/fda-dings-alar-over-extremely-concerning-ketamine-claims","hreflang":"en"}}]}
RegulatoryketamineNegative
AI Analysis
Summary
The FDA issued an untitled letter to Alar Pharmaceuticals for making concerning ketamine-related claims in exhibit booth materials and brochures at a recent conference.
Outcome Details
FDA sent untitled letter regarding exhibit booth display and brochure claims about ketamine
Importance:5/10
Sentiment:
-0.80
FDAregulatory warningmarketing claimsketamineuntitled letter
Read the original article
Published by FiercePharma on August 31, 2026 10:08 AM